Logo Image
|Articles|February 10, 2014

Certara Offers TQT Assessment Tool

Product helps to determine whether a drug candidate prolongs cardiac repolarization, a surrogate for potentially-fatal arrhythmias

Certara, which offers software and scientific consulting services for drug development, announced the launch of itsPhoenix QT+ cardiac safety assessment tool. This product provides data processing, statistical, and modeling capabilities in regard to Thorough QT (TQT) study requirements under the ICH E14 Guidelines (ICH, 2005). The product provides a comprehensive analysis of electrocardiogram (ECG) interval data collected in TQT studies and sub-studies in other clinical trials to determine whether a drug is at risk for cardiac depolarization prolongation.

Read the full release here.

Related to this article

View more
© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
What "Patient Voice" Actually Requires: Beyond the Buzzword
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Read more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more